Evidence map›Paper›PMID 26627450›Full record

Trial reportBritish journal of haematology2016

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.

Ranjana H Advani, Stephen M Ansell, Mary J Lechowicz, Anne W Beaven, Fausto Loberiza, Kenneth R Carson, Andrew M Evens, Francine Foss, Steven Horwitz, Barbara Pro and 5 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01336933 (A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone), which is not on this map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01336933 phase2completednot on this map

A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma

TypeinterventionalSponsorUniversity of NebraskaRan2011 to 2016Enrolled34ConditionsAnaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell LymphomaArmsprednisone, cyclophosphamide, etoposide, Vincristine, pralatrexate
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Peripheral T-Cell Lymphoma: What's Next?Hematological oncology · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. BV and beyond: how to incorporate novel agents into PTCL management.Hematology. American Society of Hematology. Education Program · 2024
    Review
  12. Failing Forward in Peripheral T-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Article
  13. Review
  14. Article
  15. Review
  16. Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Article
  17. Review
  18. Review
  19. Review
  20. Programmed cell death, redox imbalance, and cancer therapeutics.Apoptosis : an international journal on programmed cell death · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 14 institutions in 2 countries.

Ranjana H AdvaniMedical Oncology, Stanford Cancer Institute, Stanford, CA, USA.
Stephen M AnsellDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Mary J LechowiczWinship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Anne W BeavenMedicine-Oncology, Duke University Medical Center, Durham, NC, USA.
Fausto LoberizaDivision of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Kenneth R CarsonDivision of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Andrew M EvensDivision of Hematology/Oncology, Tufts Medical Center, Boston, MA, USA.
Francine FossYale University Cancer Center, New Haven, CT, USA.
Steven HorwitzHematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Barbara ProMedical Oncology, Jefferson University Hospital, Philadelphia, PA, USA.
Lauren C Pinter-BrownHematology/Oncology, UCLA Geffen School of Medicine, Los Angeles, CA, USA.
Sonali M SmithCenter for Advanced Medicine, University of Chicago, Chicago, IL, USA.
Andrei R ShustovClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Kerry J SavageCentre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
Julie M VoseDivision of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
University of Nebraska Medical Center · USBC Cancer Agency · CADuke Medical Center · USEmory University · USFred Hutch Cancer Center · USMayo Clinic in Arizona · USMemorial Sloan Kettering Cancer Center · USStanford Cancer InstituteThomas Jefferson University Hospital · USTufts Medical Center · USUniversity of California, Los Angeles · USUniversity of Chicago · USWashington University in St. Louis · USYale University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Peripheral T-cell lymphomas (PTCL) have suboptimal outcomes using conventional CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. The anti-folate pralatrexate, the first drug approved for patients with relapsed/refractory PTCL, provided a rationale to incorporate it into the front-line setting. This phase 2 study evaluated a novel front-line combination whereby cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternated with pralatrexate (CEOP-P) in PTCL. Patients achieving a complete or partial remission (CR/PR) were eligible for consolidative stem cell transplantation (SCT) after 4 cycles. Thirty-three stage II-IV PTCL patients were treated: 21 PTCL-not otherwise specified (64%), 8 angioimmunoblastic T cell lymphoma (24%) and 4 anaplastic large cell lymphoma (12%). The majority (61%) had stage IV disease and 46% were International Prognostic Index high/intermediate or high risk. Grade 3-4 toxicities included anaemia (27%), thrombocytopenia (12%), febrile neutropenia (18%), mucositis (18%), sepsis (15%), increased creatinine (12%) and liver transaminases (12%). Seventeen patients (52%) achieved a CR. The 2-year progression-free survival and overall survival, were 39% (95% confidence interval 21-57) and 60% (95% confidence interval 39-76), respectively. Fifteen patients (45%) (12 CR) received SCT and all remained in CR at a median follow-up of 21·5 months. CEOP-P did not improve outcomes compared to historical data using CHOP. Defining optimal front line therapy in PTCL continues to be a challenge and an unmet need.

Indexed as

AdultAgedAged, 80 and overAminopterinAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDisease-Free SurvivalDisease ProgressionEpirubicinFemaleHumansKaplan-Meier EstimateLymphoma, T-Cell, PeripheralMaleMiddle AgedPrednisone10-propargyl-10-deazaaminopterinAminopterinCyclophosphamideEpirubicinPrednisoneVincristineclinical trialsT-cell lymphomatherapy

Identifiers

PMID26627450
PMCPMC5642048
OpenAlexW2182872902

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.